Company / Working Capital
Matinas BioPharma Holdings, Inc. Working Capital History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$5.4M
FY2024
5-year range
$5.4M / $58.0M
FY2020-FY2024
Trend
-58.5%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Working Capital has declined for 4 consecutive years, from $58M in FY2020 to $5M in FY2024.
Based on SEC 10-K filings.
$5M in FY2024 with a 5-year CAGR of -27.5%.
Declined from $30M to $5M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -51.4%
- 5-Year CAGR
- -27.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- Matinas BioPharma Holdings, Inc.'s working capital has declined for 4 consecutive years.
- 5-year CAGR of -27.5%, indicating a declining trend.
- In FY2024, working capital decreased 58.5% year-over-year.
- Peak working capital was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $5.4M | -58.5% |
| FY2023 | $12.9M | -57.3% |
| FY2022 | $30.2M | -35.2% |
| FY2021 | $46.6M | -19.6% |
| FY2020 | $58.0M | +116.2% |
| FY2019 | $26.8M | +161.8% |
| FY2018 | $10.2M | +78.5% |
| FY2017 | $5.7M | +83.9% |
| FY2016 | $3.1M | +28.4% |
| FY2015 | $2.4M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026